DBV Technologies Q3 net loss widens 94% to $64.5 million
- DBV Technologies’ third-quarter 2026 net loss widened 94% year over year to $64.5 million.
- Operating expenses climbed 79% year over year to $66.3 million.
- Cash and cash equivalents totaled $165.7 million at September 30, 2026, funding operations into the third quarter of 2027.
- The VIASKIN Peanut Patch application for children aged 4–7 was submitted to the FDA, with Priority Review requested.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DBV Technologies SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610281647PRIMZONEFULLFEED1001280507) on October 28, 2026, and is solely responsible for the information contained therein.